Drug
Aflibercept
Aflibercept: highest development phase Post-Market, developed by AbbVie, Bayer, Regeneron and others. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- AbbVie, Bayer, Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Aflibercept NCT01495208 | Post-Market | Fibrovascular Pigment Epithelial Detachment |
| Aflibercept (BAY86-5321, Eylea) NCT06591598 | Post-Market | Diabetic Macular Edema |
| aflibercept 2.0 mg NCT01543568 | Post-Market | Age Related Macular Degeneration |
| Aflibercept NCT05296447 | Phase 2 | Diabetic Retinopathy, DR |
| aflibercept NCT01652196 | Phase 2 | Mucinous Adenocarcinoma of the Colon |
| Aflibercept NCT01988246 | Phase 1/2 | Diabetic Retinopathy |
| Aflibercept NCT03396861 | Phase 1 | Irvine-Gass Syndrome |
| aflibercept (AVE0005) NCT00545246 | Phase 1 | Neoplasms |
Latest
No recent events.
Follow Aflibercept on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.